Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy, Pharmacokinetics, and Safety of CSL312 in Subjects With Hereditary Angioedema
Brief Summary: This is a multicenter, randomized, placebo-controlled, parallel-arm, phase 2 study to investigate the clinical efficacy, pharmacokinetics, and safety of CSL312 as prophylaxis to prevent attacks in subjects with HAE.


Options:
A: Arm Label: rhC1INH twice weekly; Type: EXPERIMENTAL; Interventions: Biological: Recombinant human C1 inhibitor | Arm Label: rhC1INH once weekly; Type: EXPERIMENTAL; Interventions: Biological: Recombinant human C1 inhibitor | Arm Label: Placebo (Saline) twice weekly; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Recombinant human C1 inhibitor; Assigned to Arm(s): rhC1INH once weekly, rhC1INH twice weekly | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo (Saline) twice weekly
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: CSL312 (low); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Arm Label: CSL312 (med); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Arm Label: CSL312 (high); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Arm Label: CSL312 (med/high); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Intervention Type: BIOLOGICAL; Name: Factor XIIa antagonist monoclonal antibody; Assigned to Arm(s): CSL312 (high), CSL312 (low), CSL312 (med), CSL312 (med/high) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: DX-2930 300 mg every 2 weeks; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 - 300mg/2wk | Arm Label: DX-2930 300 mg every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 - 300mg/4wk | Arm Label: DX-2930 150 mg every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 - 150mg/4wk | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DX-2930 - 300mg/2wk; Assigned to Arm(s): DX-2930 300 mg every 2 weeks | Intervention Type: DRUG; Name: DX-2930 - 300mg/4wk; Assigned to Arm(s): DX-2930 300 mg every 4 weeks | Intervention Type: DRUG; Name: DX-2930 - 150mg/4wk; Assigned to Arm(s): DX-2930 150 mg every 4 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: BCX7353 110mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 capsules | Arm Label: BCX7353 150mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: BCX7353 capsules; Assigned to Arm(s): BCX7353 110mg once daily | Intervention Type: DRUG; Name: BCX7353 capsules; Assigned to Arm(s): BCX7353 150mg once daily | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): Placebo

Answer: B